← Return to Thoughts on Prolia?

Discussion

Thoughts on Prolia?

Osteoporosis & Bone Health | Last Active: Jun 7 1:45pm | Replies (45)

Comment receiving replies
@gravity3

I tolerated alendronate very well for 5 years. Now on shots 7 of Evenity. Any reason why I shouldn't go back on alendronate after evenity I stead of prolia or other thoughts.

Jump to this post


Replies to "I tolerated alendronate very well for 5 years. Now on shots 7 of Evenity. Any reason..."

The Evenity website suggests Prolia. Amgen makes both! I see that as sort of like an ad!

My docs use Reclast but alendronate is good too. My docs won't use Prolia because of the risks in getting off.

Do you know of anyone who has successfully come off of Prolia? I have been on it for 2 years. I do have a history of vetebral compression fractures. I was not made aware of the issues of coming off it before I started. My endocrinologist wants me to be on it for at least another year. Dr. McCormack recommends only 2 years. I do wish to come off due to the issues that can arise, however, I am concerned about doing that very thing because of all those same issues. . I am very concerned. Any thoughts.

I've been researching this very question and recently found a study about the different treatment sequences you're discussing. It gets a bit technical, though there are charts included that are very helpful (I'm a visual person).

Here's the link followed by a couple of excerpts that provide an overview:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567484/
"The primary objective of these post hoc analyses was to compare the probabilities of achieving a T‐score > −2.5 at the total hip or lumbar spine over 3 years with alendronate treatment alone versus treatment sequences of 12 months of romosozumab followed by 2 years of alendronate, or 12 months of romosozumab followed by 2 years of denosumab. An additional objective was to compare the probabilities of achieving non‐osteoporotic BMD T‐scores over 1 year of treatment with romosozumab compared with alendronate."
"After 3 years of treatment, during which those patients initially randomized to romosozumab had switched to either denosumab or alendronate, the probability of reaching a total hip or lumbar spine T‐score above −2.5 was dependent on treatment sequence."